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Screening for secondary hypertension (HTN) is recom-
mended for early-onset HTN. However, there have been
few studies on secondary HTN in young adults. We
aimed to investigate the prevalence and risk factors for
secondary HTN in young male military personnel. In this
retrospective cross-sectional study, hypertensive men (age,
19-29 years) were identified using the electronic medi-
cal records (EMR) database between 2011 and 2017.
Among them, patients with secondary HTN were con-
firmed through a review of the EMR. Using clinical char-
acteristics and laboratory findings, independent predic-
tors associated with secondary HTN were identified by
binary logistic regression analysis. Secondary HTN was
confirmed in 140 of 6373 participants (2.2%). Overall,
the most common causes were polycystic kidney disease
(n = 47, 0.74%) and renal parenchymal diseases (n =
24, 0.38%). The independent predictors of secondary
HTN were abnormal thyroid function test (TFT) (odds ratio
[OR]: 9.50, 95% confidence interval [CI]: 4.84-19.45, P
< 0.001), proteinuria (≥ trace) (OR: 6.13, 95% CI: 2.97-
12.99, P < 0.001), hematuria (≥ trace) (OR: 4.37, 95%
CI: 2.15-9.01, P < 0.001), severe HTN (≥ 180/110
mmHg) (OR: 3.07, 95% CI: 1.42-6.65, P = 0.004),
and non-overweight (OR: 3.03, 95% CI: 1.69-5.26, P <
0.001). However, there were no significant differences in
the family history of HTN, headache, total cholesterol, and
diabetes between patients with primary and secondary
HTN. Therefore, to ensure cost-effectiveness, screening for
secondary HTN in young hypertensive men should be per-
formed selectively considering abnormal TFT, proteinuria,
hematuria, severe HTN, and non-overweight.
Keywords
Epidemiology; hypertension; military personnel; prevalence; young
adult
1. Introduction
Secondary hypertension (HTN) is defined as HTN with an
identifiable cause, which may be treatable with specific interven-
tions. If the underlying cause is identified and treated before the
age of 30-40 years, blood pressure (BP) is likely to normalize.
However, if the cause is treated later in life, HTN may persist be-
cause long-standing high BP results in damage to the arterial sys-
tem and other organs (Streeten et al., 1990). Therefore, the guide-
lines from North America and Europe suggest screening for sec-
ondaryHTN in patients with early-onset (age< 30-40 years) HTN,
particularly without other risk factors (such as obesity, metabolic
syndrome, and family history) (Rimoldi et al., 2014; Unger et al.,
2020;Whelton et al., 2018;Williams et al., 2018). Common causes
of secondary HTN are known to be renal parenchymal disease,
primary aldosteronism, renal artery stenosis, obstructive sleep ap-
nea, pheochromocytoma, Cushing's syndrome, and thyroid dis-
ease. Thus, screening tests for secondary HTN could include renal
ultrasound or computed tomography (CT), overnight dexametha-
sone suppression test (DST) or 24-h urinary free cortisol (UFC),
and thyroid function test (TFT), and evaluation of plasma aldos-
terone/renin ratio (ARR) and plasma metanephrines (Rimoldi et
al., 2014; Unger et al., 2020; Whelton et al., 2018; Williams et al.,
2018). However, screening should be individualized, and history
taking and physical examinations should guide the choice of in-
vestigations rather than all patients requiring these excessive in-
vestigations.
The prevalence of secondary HTN in hypertensive patients is
reportedly 5%-15% (Anderson et al., 1994; Danielson and Damm-
ström, 2009; Omura et al., 2004; Sinclair, 1987). Unlike the preva-
lence of primary HTN, which increases with age, (Chow, 2013;
Jago, 2006; Zhou et al., 2017) the prevalence of secondary HTN
is the highest in preschool children (51%), (Gupta-Malhotra et al.,
2015) the lowest in younger adults aged < 30 years (5.6%), and
increases gradually in patients aged up to≥ 70 years (17.4%) (An-
derson et al., 1994). Although there have been many studies on
secondary HTN over the decades, the prevalence and predictive
factors of secondary HTN in young adults aged< 30 years are not
well known. Considering the rarity and importance of secondary
HTN, it is necessary to screen individuals who are more likely to
have this condition. Although there are general clinical charac-
teristics suggestive of secondary HTN, (Mancia et al., 2013) it is
not easy for practitioners to arrive at a decision on screening a pa-
tient with early-onset secondary HTN. There are several reasons
for this: (1) secondary causes are diverse, and clinical manifes-
tations range from asymptomatic to severe; (2) some patients are
reluctant to undergo additional investigations including 24-h urine
collection because such tests are uncomfortable, costly, and time
consuming; and (3) little is known about the predictors of sec-
ondary HTN, especially in young adults.
In SouthKorea, men aged 18-35 years are obligated to complete
a 2-year military service. All recruits undergo medical checkups
to confirm eligibility at the time of enlistment. Men are exempted
from military service if their height is < 146 cm or body mass
index is < 14 or ≥ 50 kg/m2, or if they have a serious illness or
disability (Table S1 in the Supplementary Materials). During mil-
itary service, military personnel undergo annual medical exami-
nations, including BP measurements. When HTN is suspected,
they are referred to amilitary hospital for appropriate examinations
and treatment. If the referred patients are suspected of secondary
HTN based on screening tests, they are referred again to the Armed
Forces Capital Hospital, a tertiary referral hospital, and are exam-
ined by a multidisciplinary team of cardiologists, nephrologists,
and endocrinologists.
There have been many studies on secondary HTN so far, but
little is known about secondary HTN in young adults aged < 30
years. Therefore, we aimed to investigate the prevalence and pre-
dictors of secondary HTN in relatively healthy young men aged
19-29 years using recent data from South Korean military hospi-
tals. This study could increase cost-effectiveness by selectively
screening for secondaryHTN in young adult hypertensive patients.
2. Materials and methods
2.1 Study design and setting
This retrospective cross-sectional study was conducted to in-
vestigate the prevalence and predictors of secondaryHTN in young
male military personnel. This study used data from the Defense
Medical Information System (DEMIS) database between January
2011 and June 2017.
2.2 Data collection and management
Patients who had a diagnosis of primary and secondary HTN
were identified from the DEMIS database. The DEMIS database
includes electronic medical records (EMR), imaging data, and lab-
oratory data from 19 military hospitals and about 1200 medical
corps in South Korea from 1997 till date. The diagnoses were
coded according to the International Classification of Diseases
10th revision (ICD-10).
Collecting primary HTN cases is relatively easy and simple us-
ing ICD-10 code 'I10'; however, this is not the case for secondary
HTN. Although ICD-10 code 'I15' is assigned to secondary HTN,
a significant number of cases with a secondary cause only have
a diagnostic code for the secondary cause without ICD-10 code
'I15', at the physician's discretion. Therefore, we first collected all
possible cases of secondary HTN with ICD-10 code 'I15' or other
codes for causative diseases (Table S2 in the Supplementary Ma-
terial). Subsequently, through meticulous reviews of EMR, we
eliminated inappropriate cases according to the exclusion crite-
ria. Exclusion criteria were designed to remove cases that failed
to meet the diagnostic criteria, those with an obvious preceding
cause such as trauma or sepsis, and those that failed to meet the
diagnostic criteria for HTN (Fig. 1) (Mancia et al., 2013). Subse-
quently, patient characteristics including clinical and demographic
information and laboratory and imaging data were extracted from
DEMIS directly into the electronic database by the author.
HTN was defined as a systolic BP ≥ 140 mmHg and/or a di-
astolic BP ≥ 90 mmHg and classified according to the 2018 Eu-
ropean Society of Hypertension/European Society of Cardiology
guidelines (Mancia et al., 2013). White coat HTN was diagnosed
when a patient had a clinic BP of≥ 140/90 mmHg in at least three
visits but had an average BP of < 130/80 mmHg in 24-h ambula-
tory BP monitoring (ABPM).
2.3 Clinical guidelines and standards for tests
To confirm the diagnosis of primary aldosteronism (PA), test
values of plasma aldosterone concentration (PAC), plasma renin
activity (PRA), and plasma ARR were obtained. Patients tak-
ing any antihypertensive medication had to undergo a medication
washout period before undergoing screening tests to avoid interfer-
ence with the renin-angiotensin-aldosterone system (RAAS). Di-
hydropyridine calcium channel blockers, β-blockers, angiotensin-
converting enzyme inhibitors, and angiotensin-II receptor block-
ers should be stopped at least 2 weeks before testing. Diuretics and
aldosterone antagonists should be withdrawn for at least 4 weeks.
If needed, slow-release verapamil and/or doxazosin can be pre-
scribed instead. When PA was confirmed in the saline loading
test, bilateral adrenal venous sampling should be performed for
subtype classification (Funder et al., 2016). For Cushing's syn-
drome, the test results of 24-h UFC and 1-mg overnight DST were
assessed (Guignat and Bertherat, 2010). Patients with positive re-
sults should be referred to the Armed Forces Capital Hospital, a
tertiary referral hospital, and re-examined by an endocrinologist.
The diagnostic criteria for subclinical hypercortisolism remain
controversial and uncertain. Considering the sensitivity and speci-
ficity of previous studies, we diagnosed subclinical hypercorti-
solism if the 24-h UFC was > 90 µg/day and (1) serum cortisol
was repeatedly > 1.8 µg/dL after 1-mg overnight DST, (2) serum
cortisol was> 1.8 µg/dL after a 4-mg low-dose DST, or (3) serum
cortisol was > 5 µg/dL after a 1-mg overnight DST (Chiodini,
2011; Martins et al., 2012).
For autosomal dominant polycystic kidney disease (ADPKD),
the presence of three or more renal cysts (unilateral or bilateral)
was considered sufficient for diagnosis in patients with a family
history. Without a family history, the presence of ≥ 10 renal
cysts in each kidney was considered sufficient for the diagnosis
of ADPKD (Chapman et al., 2015; Pei et al., 2015).
2.4 Biochemical measurements and analyses
All urine or blood samples for hormone tests except TFT
were sent from 19 military hospitals across the country to Green
Cross Laboratories, Korea's leading clinical laboratory, for anal-
yses. PAC, PRA, and 24-h UFC were assessed using radioim-
munoassay. Plasma metanephrine and normetanephrine levels
were analyzed using liquid chromatography coupled with tandem
quadrupole mass spectrometry, whereas 24-h urine metanephrine,
normetanephrine, catecholamines, and vanillylmandelic acid lev-
els were measured using high-performance liquid chromatogra-
phy.
2.5 Sample size calculation
The number of patients needed to obtain a confidence level of
95% and such that the real value is within± 0.6% of the surveyed
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Fig. 1. Patient flowchart. searching, assessment, and exclusion. HTN, hypertension. Among the 6586 cases, there were 638 cases of `possible'
secondary HTN with a diagnostic code associated with secondary HTN. After excluding 213 cases according to the exclusion criteria, 140 cases were
confirmed to have secondary HTN through a meticulous review of EMR. In contrast, the remaining 285 cases were of primary HTN, despite having
diagnostic codes associated with secondary HTN.
value was 5069. This was calculated assuming a secondary HTN
prevalence of 5%.
2.6 Statistical analysis
Data are presented as median (interquartile range) for contin-
uous variables with a non-normal distribution and as frequency
(percentage) for categorical variables. The Shapiro-Wilk normal-
ity test was used to assess normal distribution. The Wilcoxon rank
sum test with continuity correction was used to compare continu-
ous variables with a non-normal distribution. The chi-square test
(χ2) or Fisher's exact test was used to compare categorical vari-
ables.
We imputed missing data using multivariate imputation via
the chained equations package in R program under missing-at-
random assumptions. Binary logistic regression analysis was per-
formed to identify independent variables associated with an in-
creased risk for the diagnosis of secondary HTN. We included
overweight/obese, family history of HTN, hypokalemia, hema-
turia, proteinuria, ALT, prediabetes/diabetes, TFT, and severe
HTN in binary form in the first model. Multicollinearity of in-
dependent variables was checked using the variance inflation fac-
tor (VIF). A VIF value > 5 was considered indicative of multi-
collinearity. For the multivariable logistic regression model, step-
wise backward elimination based on likelihood ratios was used,
with P < 0.10 for entry and P > 0.05 for removal. Odds ra-
tios (ORs) were computed together with their 95% confidence in-
tervals (CIs). P < 0.05 was considered statistically significant.
The goodness of fit of the model was tested using the Hosmer-
Lemeshow test. Prediction accuracy was assessed using Nagelk-
erke's R-square and classification table. Statistical analyses were
performed using SPSS version 20.0 (IBM SPSS Statistics, IBM
Corporation, Armonk, NY, USA) and R version 3.4.3 (The R
Foundation for Statistical Computing, Vienna, Austria).
2.7 Ethics statement
Approval for the study was obtained from the institutional re-
view board of the Armed Forces Medical Command (institutional
review board approval number: AFMC-16057-IRB-16-045). The
requirement for written informed consent was waived because the
data were anonymous and retrospectively analyzed. The study was
designed in accordance with the ethical guidelines of the Declara-
tion of Helsinki.
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Table 1. Prevalence of secondary causes (n = 140) among
hypertensive men.
Cause of secondary HTN N (% of total HTN)
Autosomal dominant polycystic kidney disease 47 (0.74)
Renal parenchymal disease 24 (0.38)
Chronic glomerulonephritis 19 (0.30)
Atrophic kidney 2 (0.03)
Solitary kidney 2 (0.03)
Tubulointerstitial nephritis 1 (0.02)
Hyperthyroidism 23 (0.36)
Subclinical hypercortisolism 12 (0.19)
Without adrenal adenoma 9 (0.14)
With adrenal adenoma 3 (0.05)
Pheochromocytoma/paraganglioma 10 (0.14)
Renal artery stenosis 9 (0.14)
Idiopathic 4 (0.06)
Fibromuscular dysplasia 3 (0.05)
Takayasu’s arteritis 2 (0.03)
Cushing's syndrome 5 (0.08)
Hypothyroidism 3 (0.05)
Primary aldosteronism 3 (0.05)
Aldosterone-producing adenoma 2 (0.03)
Idiopathic hyperaldosteronism 1 (0.02)
Acromegaly 2 (0.03)
Hyperparathyroidism 2 (0.03)
Coarctation of the aorta 1 (0.02)
Total HTN 6373 (100)
HTN, hypertension.
3. Results
3.1 Prevalence of secondary HTN among hypertensive
patients
We initially collected 6586 cases of primary and `possible' sec-
ondary HTN from the DEMIS database using ICD-10 diagnostic
codes assigned to primary HTN (I10), secondary HTN (I15), and
various diagnoses related to secondary HTN (Table S2 in Supple-
mentaryMaterial). Among the 6586 cases, there were 638 cases of
`possible' secondary HTN with a diagnostic code associated with
secondary HTN. Of the 638 cases, 425 cases of `possible' sec-
ondary HTN were identified and analyzed after 213 cases were
excluded according to the exclusion criteria. Finally, 140 cases
(2.2% of all 6364 hypertensive cases) were confirmed to have sec-
ondary HTN through a meticulous review of EMR. In contrast, the
remaining 285 cases were of primary HTN, despite having diag-
nostic codes associated with secondary HTN (Fig. 1).
Hormone tests for hyperaldosteronism, Cushing's syndrome,
pheochromocytoma, and thyroid disease screening were per-
formed in 4311/6373 (67.6%) hypertensive patients. Imaging stud-
ies such as abdominal CT or ultrasonography were conducted for
3817/6373 (59.9%) patients to eliminate the presence of intra-
abdominal mass, ADPKD, renal atrophy, or renal artery stenosis
(Table S3 in the Supplementary Materials).
The most common causes of HTN were ADPKD (n = 47/6373,
0.74%) and renal parenchymal diseases (n = 24/6373, 0.38%),
followed by hyperthyroidism (n = 23/6373, 0.36%) and subclin-
ical hypercortisolism (n = 12/6373, 0.19%). Other endocrino-
logic causes, including pheochromocytoma/paraganglioma (n =
10/6373, 0.14%) and PA (n = 3/6373, 0.05%), were very rare (Ta-
ble 1).
3.2 Comparison of baseline characteristics between
primary and secondary HTN
The demographic, clinical, and laboratory characteristics of
patients with primary HTN (n = 285) and secondary HTN (n =
140) are summarized in Table 2. The median (interquartile range)
age of patients with primary and secondary HTN was 20.0 (20.0-
21.0) years and 21.0 (20.0-22.0) years, respectively. Both groups
had few comorbidities, such as chronic kidney disease, diabetes,
and hypercholesterolemia.
Patients with secondary HTN were more likely to be hy-
pokalemic (6.5%, n = 9/139, vs. 1.1%, n = 3/273, P = 0.009),
and to have hematuria (≥ trace) (31.3%, n = 42/134, vs. 5.9%, n
= 15/256, P < 0.001), proteinuria (≥ trace) (35.8%, n = 48/134,
vs. 5.8%, n = 15/257, P < 0.001), lower levels of alanine amino-
transferase (22.0 [16.0; 35.0], vs. 25.0 [17.0; 44.0], P = 0.045),
abnormal TFT (36.8%, n = 39/136, vs. 6.2%, n = 16/259, P <
0.001), and severe HTN (≥ 180/110 mmHg) (18.6%, n = 26/140,
vs. 6.8%, n = 19/282, P< 0.001), than those with primary HTN. In
contrast, patients with secondary HTN were less likely to be over-
weight (81.4%, n = 182/224 vs. 64.6%, n = 82/127, P = 0.001).
However, there were no significant differences in smoking his-
tory, family history of HTN (first-degree relatives), headache, to-
tal cholesterol level, diabetic state, and in-office heart rate between
the two groups.
Among the nine patients with hypokalemia in the secondary
HTN group, there were three patients with renal artery stenosis,
two patients with ADPKD, and one patient with subclinical hy-
percortisolism in addition to three patients with PA.
3.3 Prediction of secondary HTN
In multiple logistic regression analyses, six major clinical pa-
rameters were identified as predictors of secondaryHTN (Table 3):
abnormal TFT (OR: 9.50, 95% CI 4.84-19.45, P < 0.001), pro-
teinuria (≥ trace) (OR: 6.13, 95% CI 2.97-12.99, P < 0.001),
hematuria (≥ trace) (OR: 4.37, 95% CI 2.15-9.01, P < 0.001),
hypokalemia (OR: 3.79, 95% CI 0.85-17.98, P = 0.082), severe
hypertension (OR: 3.07, 95% CI 1.42-6.65, P = 0.004), and non-
overweight (BMI < 23 kg/m2) (OR 3.03, 95% CI 1.69-5.26, P
< 0.001). However, there were no significant differences in the
family history of HTN, headache, total cholesterol, and diabetes
between the groups.
The VIF values for predictive factors were < 1.1, which indi-
cated that there was no multicollinearity. The model fit the data
well (Hosmer-Lemeshow χ2 = 1.07, P = 0.998), and the amount of
explained variance was estimated at 42% (Nagelkerke's R-square
= 0.42). Although the sensitivity (60.0%) and positive predictive
value (PPV, 24.3%) were low, the specificity (90.5%) and neg-
ative predictive value (NPV, 82.2%) were good, with an overall
accuracy of 80.5%.
4. Discussion
In this study, we found that secondary HTN was very rare
(2.2%, n = 140/6373) among hypertensive military males aged
< 30 years. The most common causes of secondary HTN were
ADPKD (0.74%, n = 47/6373) and renal parenchymal diseases
(0.38%, n = 24/6373), with other endocrinologic causes such as
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Table 2. Demographic, clinical, and laboratory characteristics of study subjects.
Clinical characteristics Secondary HTN (n = 140) Primary HTN (n = 285) P-value
Age [range], years 21.0 [20.0; 22.0] 20.0 [20.0; 21.0] 0.018
Body mass index (BMI) [range], kg/m2 24.5 [22.3; 27.2] 26.0 [23.7; 29.1] 0.001
Underweight (BMI < 18.5 kg/m2) 2 (1.6%) 0 (0.0%)
Normal (18.5 ≤ BMI < 23 kg/m2) 43 (33.9%) 42 (18.8%)
Overweight/Obese (BMI ≥ 23 kg/m2) 82 (64.6%) 182 (81.2%)
Smoking, number (%) 0.289
Never 65 (55.1%) 109 (52.9%)
Past 15 (12.7%) 17 (8.3%)
Current 38 (32.2%) 80 (38.8%)
History of HTN in first-degree relatives, number (%) 66 (49.6%) 138 (57.3%) 0.19
Headache, number (%) 39 (29.8%) 73 (32.3%) 0.705
BUN [range], mg/dL 13.8 [11.4; 16.5] 13.2 [11.6; 14.7] 0.018
Creatinine [range], mg/dL 0.9 [0.8; 1.1] 1.0 [0.9; 1.1] 0.005
Serum potassium, no. (%) 0.009
Hypokalemia (K+ ≤ 3.5 mEq/L) 9 (6.5%) 3 (1.1%)
Normokalemia (3.5 < K+ ≤ 5 mEq/L) 125 (89.9%) 260 (95.2%)
Hyperkalemia (K+ > 5 mEq/L) 5 (3.6%) 10 (3.7%)
Hematuria, number (%) < 0.001
Absent (-) 92 (68.7%) 241 (94.1%)
Trace (+/-) 16 (11.9%) 7 (2.7%)
Mild (1+) 4 (3.0%) 5 (2.0%)
Moderate to severe (≥ 2+) 22 (16.4%) 3 (1.2%)
Proteinuria, number (%) < 0.001
Absent (-) 86 (64.2%) 242 (94.2%)
Trace (+/-) 25 (18.7%) 13 (5.1%)
Mild (1+) 7 (5.2%) 1 (0.4%)
Moderate to severe (≥ 2+) 16 (11.9%) 1 (0.4%)
Alanine aminotransferase (ALT) [range], IU/L 22.0 [16.0; 35.0] 25.0 [17.0; 44.0] 0.045
Total cholesterol [range], mg/dL 170.0 [145.0; 197.0] 176.0 [154.0; 198.0] 0.066
Diabetes, number (%) 0.096
Non-diabetic 117 (84.8%) 200 (91.7%)
Prediabetic 17 (12.3%) 16 (7.3%)
Diabetic 4 (2.9%) 2 (0.9%)
Thyroid function test (TFT), number (%) < 0.001
Normal 67 (63.2%) 243 (93.8%)
Subclinical hypothyroidism (high TSH) 1 (0.9%) 6 (2.3%)
Subclinical hyperthyroidism (low TSH) 5 (4.7%) 8 (3.1%)
Hypothyroidism 4 (3.8%) 0 (0.0%)
Hyperthyroidism 23 (21.7%) 0 (0.0%)
Other abnormal TFT 6 (5.7%) 2 (0.8%)
Office heart rate [range], rate/min 82.0 [74.0; 94.5] 82.0 [72.0; 95.0] 0.745
Classification of office BP* - no. (%) < 0.001
High normal (≥ 130/85 mmHg) 6 (4.3%) 5 (1.8%)
Grade 1 (≥ 140/90 mmHg) 67 (47.9%) 166 (58.9%)
Grade 2 (≥ 160/100 mmHg) 41 (29.3%) 92 (32.6%)
Grade 3 (≥ 180/110 mmHg) 26 (18.6%) 19 (6.7%)
Isolated systolic HTN 51 (36.4%) 121 (43.1%) 0.231
Hypertension (HTN), blood urea nitrogen (BUN), thyroid-stimulating hormone (TSH), blood pressure (BP).
*Office BP and heart rate values are the average of measurements before taking antihypertensive drugs. Hypertension was defined and
classified according to the 2018 European Society of Hypertension/European Society of Cardiology guidelines:
High normal: systolic 130-139 mmHg and/or diastolic 85-89 mmHg.
Grade 1: systolic 140-159 mmHg and/or diastolic 90-99 mmHg.
Grade 2: systolic ≥ 160-179 mmHg and/or diastolic 10-109 mmHg.
Grade 3: systolic ≥ 180 mmHg and/or diastolic ≥ 110 mmHg.
Isolated systolic HTN: ≥ 140 mmHg and diastolic < 90 mmHg.
Volume 21, Number 4, 2020 631
Table 3. Major predictive factors of secondary HTN.
Logistic regression Univariate analysis Multivariable analysis
Variables Unadjusted OR 95% CI P-value VIF Adjusted OR 95% CI P-value
Abnormal TFT 8.50 4.69-16.13 < 0.001 1.04 9.50 4.84-19.45 < 0.001
Proteinuria (≥ trace) 9.93 5.51-18.80 < 0.001 1.09 6.13 2.97-12.99 < 0.001
Hematuria (≥ trace) 7.74 4.36-14.30 < 0.001 1.06 4.37 2.15-9.01 < 0.001
Hypokalemia (K+ ≤ 3.5) 4.83 1.54-18.08 0.010 1.02 3.79 0.85-17.98 0.082
Severe HTN* 3.02 1.63-5.69 < 0.001 1.03 3.07 1.42-6.65 0.004
Non-overweight† 2.38 1.52-3.70 < 0.001 1.07 3.03 1.69-5.26 < 0.001
Thyroid function test (TFT), hypertension (HTN), odds ratio (OR), confidence interval (CI), variance inflation factor (VIF).
*Severe HTN was defined as systolic ≥ 180 mmHg and/or diastolic ≥ 110 mmHg.
In the Asian criteria, overweight is defined as BMI ≥ 23 kg/m2 (in the World Health Organization criteria, overweight is defined as BMI
≥ 25 kg/m2).
aldosteronism (0.05%, n = 3/6373) being very rare.
A previous study conducted from 1974 to 1991 in the United
States reported that secondary causes were noted in 5.6% of pa-
tients aged 18-29 years who were referred for severe HTN (Co-
hen, 2017). Another study conducted from 1995 to 1999 in Japan
demonstrated that the prevalence of secondary HTN was 9.1%
among 1020 hypertensive patients in an outpatient clinical setting
(Omura et al., 2004). However, the study did not describe in detail
the age-related prevalence of secondary HTN. To the best of our
knowledge, there has been no previous study on the prevalence of
secondary HTN in young adults < 30 years of age.
Themain reasons for the lower prevalence of secondaryHTN in
this study could be explained by the following two reasons. First,
most of the 1200medical corps in South Korea are in charge of pri-
mary care; however, they do not have antihypertensive drugs and
cannot perform screening tests for secondary HTN. Therefore, in
most cases where hypertensive patients are identified by a primary
physician in the medical corps, patients are referred to a nearby
military hospital for screening and treatment. This peculiarity of
military medical systems makes the denominator large in calculat-
ing the prevalence of secondary HTN, hence the low prevalence.
Second, as new recruits undergo multiple tests at the time of en-
listment, a significant number of cases of secondary HTN would
have been newly detected, and the affected individuals would be
exempted from military service (Table S1 in the Supplementary
Appendix). This could have reduced the number of patients with
secondary HTN and increased the total number of hypertensive
patients, resulting in a lower prevalence of secondary HTN.
Previous studies have reported that renal disease was the most
common cause of secondary HTN (Anderson et al., 1994; The
Japanese Society of Hypertension, 2014). However, most of them
did not specify ADPKD as an important single disease entity.
ADPKD is the most common hereditary kidney disease and ac-
counts for about 10% of end-stage renal disease (ESRD) cases re-
quiring renal replacement therapy (Spithoven et al., 2014). Early
detection of ADPKD and rigorous BP control are associated with
improvement in clinical markers and delay in the onset of ESRD
(Schrier et al., 2014, 2003). Surprisingly, however, a previous
study on HTN in young adults with ADPKD revealed that only
7% of the subjects had been screened for ADPKD (Kelleher et al.,
2004). Normal findings in routine laboratory tests are not a basis
for excluding ADPKD, and ultrasound has a low diagnostic sensi-
tivity for ADPKD screening in individuals aged< 30 years (Pei et
al., 2009). In this study, ADPKD was found to be the most com-
mon cause of HTN, which could be attributed to the fact that CT
was performed in up to 56.9% of all subjects.
Recent studies have shown that PA is more prevalent in patients
with severe or resistant HTN than previously thought (Fagugli and
Taglioni, 2011). According to a recent systematic review, however,
there were wide variations in prevalence and large heterogeneity in
primary care settings (3.2%-12.7%, I2 = 57.6% [0%-78%]) and re-
ferral centers (1.0-29.8%, I2 = 97.1% [96.7-97.5%]) (Käyser et al.,
2016). In addition, a population-based study documented that pos-
itive screening results for PAwere obtained in 0.2-7.0% of the gen-
eral hypertensive population, which was less than that reported in
a previous study on referred hypertensive patients (Hannemann et
al., 2012). Although hypokalemia is a characteristic finding in PA,
it can also manifest in renal artery stenosis, ADPKD, and subclini-
cal hypercortisolism as a result of RAAS activation (Schrier et al.,
2014; The Japanese Society ofHypertension, 2014). Such cases are
differentiated from PA by high renin levels and low ARR. Monti-
cone et al. reported that of 1672 general hypertensive patients (age,
46± 9.2 years) from Italy, 232 patients (13.8%) had an ARR> 30
together with a PAC > 10 ng/dL, and 99 patients (5.9%) were di-
agnosed with PA (Monticone et al., 2017). According to the result
of the Bussolengo study, the prevalence of elevated ARR (≥ 32)
increased with age from 15% (age 35-44 years) to 38% (age 55-
74) (Olivieri et al., 2004). From this, it could be inferred that the
prevalence of elevated ARR may be lower in younger age groups.
In the present study, of the 6373 hypertensive patients, only 5
patients (0.08%) had an ARR > 30, together with a PAC > 10
ng/dL, and 3 patients (0.05%) were diagnosed with PA. Of the
3 patients with PA, the ARR was 182.7; 170.0 in 2 patients with
aldosterone-producing adenoma (APA) and 24.0 in 1 patient with
idiopathic hyperaldosteronism (IHA). There are three possible ex-
planations for why the prevalence of PA in this study is much lower
than that reported in other studies. First, the subjects of this study
were much younger (mean age, 21 years) than those of other stud-
ies. Second, although IHA is usually more than twice as common
as APA, ARR is not very high in patients with IHA; thus, it could
have been under detected. Most importantly, as noted above, it is
possible that a significant number of patients with secondary HTN
were excluded from the study population owing to health checkups
at the time of enlistment (Table S1 in the SupplementaryMaterial).
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Subclinical hypercortisolism had not been determined as a
cause of HTN in previous reports until its prevalence was re-
ported to be 1.0% of all hypertensive patients in 2004 (Omura et
al., 2004). Although the diagnostic criteria are complex and con-
troversial, subclinical hypercortisolism should be considered as a
cause of resistant HTN, as it is associated with increased comor-
bidities and mortality (Martins et al., 2012). In this study, sub-
clinical hypercortisolism was the fourth most common cause of
secondary HTN (0.19%).
Multiple logistic regression analysis revealed five major pre-
dictive factors for secondary HTN. Abnormal TFT results had the
strongest association with secondary HTN (Table 3). TFT is im-
portant for the diagnosis of hyperthyroidism or hypothyroidism as
a cause of HTN, and other abnormal TFT findings were also more
prevalent in secondary HTN. Further studies will be required to
ascertain the correlation between other abnormal TFT results and
secondary causes of HTN.
Abnormal findings in urine dipstick tests for blood and pro-
tein can occur transiently and functionally for various reasons,
especially in young patients. In this study, however, these were
much more prevalent in patients with secondary HTN, mainly due
to renal parenchymal diseases and ADPKD. Of note, even trace
amounts of proteinuria or hematuria were suggestive of secondary
HTN.
Being overweight/obese (BMI ≥ 23 kg/m2) appeared to be a
protective factor against secondary HTN (OR: 0.33, 95% CI 0.19-
0.59, P < 0.001). The accumulation of excess adipose tissue in-
troduces a cascade that elevates BP, causing obesity-induced hy-
pertension (Cohen, 2017; Leggio et al., 2017). Thus, it is presumed
that overweight/obese hypertensive patients are less likely to have
secondary causes of HTN even in young individuals, as obesity
itself may cause primary HTN.
Although the sensitivity and PPV of themodel were unsatisfac-
tory, the specificity (90.5%) and NPV (82.2%) were satisfactory
with an accuracy of 80.5%. In other words, if hypertensive pa-
tients do not have any predictive factors, it is likely that they will
not need to undergo further tests for secondary HTN.
4.1 Study limitations and strengths
This study has some limitations. First, as this was a retro-
spective study, there was a lack of unique, predefined criteria for
screening secondary HTN. Second, 24-h ABPM was performed
in only 31.6% of all hypertensive patients. Thus, it is possible that
the total number of hypertensive patients was exaggerated bywhite
coat HTN. Third, the EMRof only 638 patients with `possible' sec-
ondary HTNwere reviewed among the 6373 hypertensive patients.
Fourth, obstructive sleep apnea, one of the most common causes
of secondary HTN (Pedrosa et al., 2011), was not evaluated in most
patients. As obesity is a typical finding in patients with obstruc-
tive sleep apnea, if it was screened as a cause of HTN in this study,
excessive weight might have been a positive predictor rather than a
negative predictor of secondary HTN. Lastly, the existence of se-
lection bias should be considered when interpreting the results of
this study, as the study population consisted of relatively healthy
young male military personnel.
Despite these limitations, our study has several strengths. First,
this is the largest prevalence study on secondary HTN among
young hypertensive men. The study population comprised a cer-
tain, well-defined, homogeneous demographic group. In South
Korea, nearly all men are obligated to serve in the army in their
20 s, and most of them are examined in military hospitals when
suspected of having HTN. Second, as medical services at mili-
tary hospitals are free of charge, individuals can undergo screen-
ing tests for secondary HTNwithout concerns about the cost. This
was key to enabling screening for secondary HTN in up to two-
thirds of general hypertensive patients. Third, all urine or blood
specimens for hormone tests were analyzed at a single institution,
thus increasing confidence in the test results. Therefore, our find-
ings could be applied to an unselected hypertensive population in
their early 20 s without severe comorbidities, especially in military
personnel.
Secondary HTN is rare in relatively healthy hypertensive pa-
tients aged < 30 years. Therefore, in this population, screen-
ing for secondary HTN should be considered in the presence of
any predictive factors, such as abnormal TFT findings, protein-
uria, hematuria, severe HTN, or non-overweight, to ensure cost-
effectiveness.
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